ONWARD Medical NV
F:63E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of ONWARD Medical NV (63E) under the Base Case is 0.852 EUR per share. Compared with the current market price of 1.366 EUR, the stock appears Overvalued by 38% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What ONWARD Medical Does
ONWARD Medical develops implantable and external neurostimulation devices that are designed to help people with spinal cord injury and related movement disorders recover motion and function. Its main products are built around electrical stimulation of the spinal cord, which aims to activate nerve pathways that still exist but no longer work properly after injury. The company focuses on therapies that can support walking, hand use, blood pressure control, and other functions affected by spinal cord damage.
- Headquarters
- Netherlands NL
- Employees
- 137
- IPO date
- Oct 21, 2021
Balance Sheet
Recent Events
Latest Earnings Call
ONWARD paired continued ARC-EX adoption with progress across its ARC-IM pipeline, while reimbursement processes are extending some sales timing.
Open the earnings call- Stock, day of the call
- −11.5%
Past 12 months
Continue 63E Research
Decided on ONWARD Medical? Get an email when 63E reaches the price you’d buy at. Free with an account.
Other ONWARD Medical listings
What is the Intrinsic Value of one 63E stock?
The intrinsic value for ONWARD Medical NV (63E) under the Base Case is 0.852 EUR.
Is 63E stock undervalued or overvalued?
Compared with the current market price of 1.366 EUR, the stock appears Overvalued by 38% .